Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes - Wikidata - awgldk - TriplyDB

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

http://www.wikidata.org/entity/Q36906207

about

Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience Enzymatically Modified Starch Ameliorates Postprandial Serum Triglycerides and Lipid Metabolome in Growing Pigs Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial)Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial).A Practical Review of C-Peptide Testing in Diabetes Recommendations for the definition of clinical responder in insulin preservation studies Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes.Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.Gene CNVs and protein levels of complement C4A and C4B as novel biomarkers for partial disease remissions in new-onset type 1 diabetes patients Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin.Identification of autoantibody-negative autoimmune type 2 diabetic patients.Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man.Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes.Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes.Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9 Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes.Detection of β cell death in diabetes using differentially methylated circulating DNA.Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes.Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes Factors Associated with Glycemic Variability in Patients with Type 2 Diabetes: Focus on Oral Hypoglycemic Agents and Cardiovascular Risk Factors.Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.Correlations between Glucagon Stimulated C-peptide Levels and Microvascular Complications in Type 2 Diabetes Patients Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial Residual C-peptide in patients with Type 1 diabetes and multiethnic backgrounds.Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes.Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.20/(fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report.Cohort profile: the German Diabetes Study (GDS).Indices of insulin secretion during a liquid mixed-meal test in obese youth with diabetes.Effect of rituximab on human in vivo antibody immune responses.Strategies for clinical trials in type 1 diabetes Potential beneficial effects of a gluten-free diet in newly diagnosed children with type 1 diabetes: a pilot study

P2860

Q26850621-614DFB1F-D4BE-4E5F-BB7B-414EF120DE85 Q28548362-C7C5E203-F5BB-4266-B9F1-6E81834B0CE4 Q28731029-1AEFC97C-142B-47B5-9CCB-90E6B0A7163F Q28742007-CE7690F5-B163-4B12-84BA-D7BDB3E1D94B Q30521476-D7143AD1-A471-4A27-9051-DA67CD773105 Q31132948-5E451E62-7E4C-40E3-822A-C12C3419B57B Q33732640-44E4E4D6-CF06-487F-AC2D-F5FD3F7DA1F9 Q34077400-A2A1C3B9-A311-43CF-B597-DA62E3AD06E6 Q34079225-60413B0F-2A1D-43CE-B69F-D8F8072C1A86 Q34131203-9FF542B1-29EB-46AA-83D2-0A1FBB699218 Q34237680-F279D4B1-5484-4146-921A-69A2FF445D2A Q34260546-F37C1FC9-06F0-4EC9-98A6-4315765BBF94 Q34297738-369EADED-0560-4558-97C4-8C0A3505C58F Q34419575-45939C91-A580-439F-8514-A5AED73301DD Q34448607-BA454948-8712-4EEA-BC58-C3E17A93D140 Q34507037-39F3679E-9FA6-4322-910E-D5E83C14835B Q34583267-897C16E5-2890-4E1B-96ED-AC82849ACFD0 Q34718808-2AF6CDCE-A94A-41D0-B6B5-BEE9D28B0692 Q34979018-289B09B4-C2CF-4C62-ACD9-FA2CEF92D5CC Q35147560-A4F9045C-D1C0-44D9-97F8-51CA35D9D7CA Q35360844-BA1F0C55-0409-4B47-A9D2-E8B2CD4F3DAB Q35561483-01F26091-6D9C-4985-8939-F5D91FB7B787 Q35571341-81457F7E-00EC-4EBD-85A1-1CB455F835D3 Q35797043-98049F65-9892-49CE-962A-9E990BEF780C Q35891952-9D6209AE-6EA9-42F6-B448-84FBC407EEBC Q36001688-986B67E9-B8F8-456B-9A36-45E51D3BE2B7 Q36127615-C700ECE7-7E14-46F3-B4CB-F09D3FE7ED72 Q36182476-A7C0D5B8-642E-44D3-9D07-CE12C0A83E57 Q36292592-EFDEF7AA-A0D5-4650-8D28-B3D9FC5849E8 Q36365246-498ADD45-4F07-4316-BA09-C5DF51658A78 Q36510973-024567F4-955B-4DB6-BB26-88D9A9C0F5A6 Q36555009-9FE1CD90-B2D3-43D9-9FD4-834F1D9DBE22 Q36560230-CC5A8764-D1F5-4825-964B-E1995B7D599B Q36632019-5F7C73A0-184C-4188-9DC9-3FD3EB33F08C Q36716300-6065C57B-8053-4A59-BEF0-9EABFCCCE127 Q36774677-C321904D-8D18-4CA8-9A45-003E66382350 Q36799549-167A5442-E325-4595-825D-B8F7FF5799E0 Q36860483-4C13A6A9-FB9B-491E-A1D7-45B032801A2D Q36995370-0C8A22F2-842D-4E25-B2A2-4CF7B586EBFF Q37075420-ACB5A693-DEBC-4AE9-B200-A4CE5139C4AF

P2860

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

http://www.wikidata.org/entity/Q36906207

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Mixed-meal tolerance test vers ...... utic trials in type 1 diabetes

@en

type

label

Mixed-meal tolerance test vers ...... utic trials in type 1 diabetes

@en

prefLabel

Mixed-meal tolerance test vers ...... utic trials in type 1 diabetes

@en

P1433

Q36906207-4D80401B-0082-4B40-A8C0-5E21C4E77468

P1476

Q36906207-1A283F7E-60CC-4292-9C52-77F16251E7F1

P2093

Q36906207-2960B7F8-C9CB-4E6A-829D-86C5E3B3A0B5

Q36906207-3FDE9FBC-BF96-4469-A90D-9CB7BF58668D

Q36906207-55669D9C-3D7A-468D-8D13-79307A3B9A61

Q36906207-743040F8-D5B7-42CC-A0A1-82E2692C681E

Q36906207-8716D32D-4B4D-4C8C-92CE-011CB6EF039A

Q36906207-9639524D-B23C-4C02-B4F0-504D45A74E3F

Q36906207-A5AB0F36-1078-466A-91F5-4719A9759B35

Q36906207-F76A7708-C555-4D21-9230-B19EAEF61DCE

P2860

Q36906207-3331ADE1-1572-4C7C-B94B-F770DEF24C30

Q36906207-349E1506-B2BA-4579-A97F-BC5255D8F34E

Q36906207-4C9E7A32-EA64-41C8-B8C1-09BEF83C335E

Q36906207-783A9B4D-E99A-4EFB-89C5-6DE00EC48871

Q36906207-8F845F2B-7F24-4A45-A135-3F6A3FD4D540

Q36906207-AA85CB08-E5C5-45A9-BF64-3A5D48026039

Q36906207-C22B57EC-FEF7-4BEF-B59D-378CB844E04C

P304

Q36906207-ACBEE22C-EFD3-4940-80AB-88D333BC6928

P31

Q36906207-B965C524-6E9B-4A38-8141-59ACB26B6720

P356

Q36906207-0B2424BC-DE74-435B-B993-45D7FDDD99CE

P407

Q36906207-BE38F3FC-998F-4DE8-878F-7214D908A018

P433

Q36906207-898693CC-8C7D-4C46-B1E7-52D5F3B1A21B

P478

Q36906207-029B7AD5-F1A8-49D7-A205-2C00A38B030D

P50

Q36906207-255A574A-5D1F-4096-8B75-26D8A6A95098

Q36906207-32E2908C-F65D-4974-940A-44EE6A325B1C

Q36906207-829B3A5F-BBE9-4F01-BFB2-1FFFB0701419

P577

Q36906207-8DED05E3-E868-4D84-876C-3FB74CAF0092

P5875

Q36906207-F23CC7D9-21E7-4884-B343-03B780C9C4F5

P698

Q36906207-5C03919C-6E56-4E6E-88B8-51D38275FD5C

P921

Q36906207-9DE659BA-8783-40D4-A250-EFAF27DC8430

P932

Q36906207-0481E9F6-E915-4AFC-AED9-A633F710BDB4

P356

P1433

P1476

Mixed-meal tolerance test vers ...... utic trials in type 1 diabetes

@en

P2093

Burkhard Haastert

http://www.w3.org/2001/XMLSchema#string

Carla J Greenbaum

http://www.w3.org/2001/XMLSchema#string

European C-Peptide Trial Study Group

http://www.w3.org/2001/XMLSchema#string

Hubert Kolb

http://www.w3.org/2001/XMLSchema#string

Paolo Pozzilli

http://www.w3.org/2001/XMLSchema#string

Paula Friedenberg McGee

http://www.w3.org/2001/XMLSchema#string

Thomas Mandrup-Poulsen

http://www.w3.org/2001/XMLSchema#string

Type 1 Diabetes Trial Net Research Group

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

The role of measurement reliability in clinical trials.

Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.

The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes.

Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes.

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

Random C-peptide in the classification of diabetes.

P304

1966-1971

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC07-2451

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Johnny Ludvigsson

Tadej Battelino

P577

2008-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51403481

http://www.w3.org/2001/XMLSchema#string

P698

18628574

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

2551636

http://www.w3.org/2001/XMLSchema#string